Literature DB >> 34473323

Proteomic Mapping of the Human Myelin Proteome.

Paul C Guest1.   

Abstract

Alzheimer's disease (AD) is a degenerative cognitive condition that affects individuals with an increasing prevalence in older age groups. There are currently five drugs on the market for AD but no new effective ones have been discovered for decades. There has been increasing interest in the use of natural remedies such as special diets and plant extracts but these require further study. Based on the known effects on white matter and neuronal conductance in Alzheimer's disease, we present a protocol for proteomic analysis of myelin-enriched brain fractions as a way of identifying potential biomarkers of efficacy. This fingerprint could be used in screening assays for novel compounds for treatment of AD.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Biomarker; Drug target; Myelin; Oligodendrocytes; Pathway; Proteome

Mesh：

Substances：

Year:  2022        PMID： 34473323     DOI： 10.1007/978-1-0716-1558-4_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  7 in total

Review 1.  A new perspective of the hippocampus in the origin of exercise-brain interactions.

Authors:  Catarina Rendeiro; Justin S Rhodes
Journal:  Brain Struct Funct       Date:  2018-04-18       Impact factor: 3.270

2.  Brain region-specific amyloid plaque-associated myelin lipid loss, APOE deposition and disruption of the myelin sheath in familial Alzheimer's disease mice.

Authors:  Ibrahim Kaya; Eva Jennische; Stefan Lange; Ahmet Tarik Baykal; Per Malmberg; John S Fletcher
Journal:  J Neurochem       Date:  2020-03-25       Impact factor: 5.372

3.  Mediterranean diet and 3-year Alzheimer brain biomarker changes in middle-aged adults.

Authors:  Valentina Berti; Michelle Walters; Joanna Sterling; Crystal G Quinn; Michelle Logue; Randolph Andrews; Dawn C Matthews; Ricardo S Osorio; Alberto Pupi; Shankar Vallabhajosula; Richard S Isaacson; Mony J de Leon; Lisa Mosconi
Journal:  Neurology       Date:  2018-04-13       Impact factor: 9.910

4.  The effects of an extensive exercise programme on the progression of Mild Cognitive Impairment (MCI): study protocol for a randomised controlled trial.

Authors:  Kate E Devenney; Marit L Sanders; Brian Lawlor; Marcel G M Olde Rikkert; Stefan Schneider
Journal:  BMC Geriatr       Date:  2017-03-22       Impact factor: 3.921

5.  The effect of an interactive cycling training on cognitive functioning in older adults with mild dementia: study protocol for a randomized controlled trial.

Authors:  E G A Karssemeijer; W J R Bossers; J A Aaronson; R P C Kessels; M G M Olde Rikkert
Journal:  BMC Geriatr       Date:  2017-03-21       Impact factor: 3.921

Review 6.  Curcumin and Resveratrol in the Management of Cognitive Disorders: What is the Clinical Evidence?

Authors:  Gabriela Mazzanti; Silvia Di Giacomo
Journal:  Molecules       Date:  2016-09-17       Impact factor: 4.411

7.  White matter alterations in Alzheimer's disease without concomitant pathologies.

Authors:  I Ferrer; P Andrés-Benito
Journal:  Neuropathol Appl Neurobiol       Date:  2020-05-01       Impact factor: 8.090
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.